AstraZeneca PLC is 54.5x more valuable than Apellis Pharmaceuticals, Inc. by market capitalization ($286.27 B vs $5.25 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | APLS | AZN |
|---|---|---|
| Market cap | $5.25 B | $286.27 B |
| US-listed rank | #1353 | #45 |
| Revenue (latest FY) | $1.00B | - |
| Net income (latest FY) | $22.39M | - |
| Net margin | 2.2% | - |
| P/E (trailing FY) | 234.6 | - |
| SEC filings | 1,217 | 1,004 |
AstraZeneca PLC is 54.5x more valuable than Apellis Pharmaceuticals, Inc. by market capitalization ($286.27 B vs $5.25 B).
Full pages: Apellis Pharmaceuticals, Inc. and AstraZeneca PLC, or browse the full rankings.